VIVS
VivoSim Labs Inc
$
2.700
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.950
Open
2.570
VWAP
2.56
Vol
693.71K
Mkt Cap
7.02M
Low
2.350
Amount
1.78M
EV/EBITDA(TTM)
--
Total Shares
2.60M
EV
-2.04M
EV/OCF(TTM)
--
P/S(TTM)
33.91
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The Company offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. It uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The Company's 3D human tissue platform is multifaceted. The Company has expertise in 3D organoids, such as spheroids, and has made advances in proprietary cell culture techniques including ratios, components and conditions.
Show More
Valuation Metrics
The current forward P/E ratio for VivoSim Labs Inc (VIVS.O) is -0.30, compared to its 5-year average forward P/E of -0.25. For a more detailed relative valuation and DCF analysis to assess VivoSim Labs Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-0.25
Current PE
-0.30
Overvalued PE
-0.17
Undervalued PE
-0.32
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
21.65
Current PS
2.70
Overvalued PS
31.18
Undervalued PS
12.12
Financials
Annual
Quarterly
FY2026Q1
YoY :
-5.13%
37.00K
Total Revenue
FY2026Q1
YoY :
-13.91%
-2.92M
Operating Profit
FY2026Q1
YoY :
-14.98%
-2.84M
Net Income after Tax
FY2026Q1
YoY :
-58.39%
-1.14
EPS - Diluted
FY2026Q1
YoY :
+32.08%
-3.94M
Free Cash Flow
FY2026Q1
YoY :
+5.41%
100.00
Gross Profit Margin - %
FY2026Q1
YoY :
-56.59%
-7.35K
FCF Margin - %
FY2026Q1
YoY :
-10.39%
-7.68K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
VIVS News & Events
Events Timeline
2025-08-14 (ET)
2025-08-14
08:14:45
VivoSim appoints Lialin as Chief Commercial Officer
Sign Up For More Events
Sign Up For More Events
News
9.5
10-30BenzingaAlphabet Shares Rise Approximately 8%; Check Out 20 Stocks Making Moves in Premarket Trading
5.0
08-14NewsfilterVivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
Sign Up For More News
People Also Watch
AAPL
Apple Inc
270.370
USD
-0.38%
XOM
Exxon Mobil Corp
114.360
USD
-0.29%
ORCL
Oracle Corp
262.610
USD
+2.23%
META
Meta Platforms Inc
648.350
USD
-2.72%
AVGO
Broadcom Inc
369.630
USD
-1.82%
AMZN
Amazon.com Inc
244.220
USD
+9.58%
WMT
Walmart Inc
101.180
USD
-1.03%
TSLA
Tesla Inc
456.560
USD
+3.74%
NVDA
NVIDIA Corp
202.490
USD
-0.20%
MSFT
Microsoft Corp
517.810
USD
-1.51%
FAQ
What is VivoSim Labs Inc (VIVS) stock price today?
The current price of VIVS is 2.7 USD — it has decreased -9.4 % in the last trading day.
What is VivoSim Labs Inc (VIVS)'s business?
What is the price predicton of VIVS Stock?
What is VivoSim Labs Inc (VIVS)'s revenue for the last quarter?
What is VivoSim Labs Inc (VIVS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for VivoSim Labs Inc (VIVS)'s fundamentals?
How many employees does VivoSim Labs Inc (VIVS). have?